Krystal Biotech (KRYS) Stock Forecast & Price Target $299.45 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$304.00 +4.55 (+1.52%) As of 05/22/2026 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Krystal Biotech - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 12 Analyst RatingsSell0Hold2Buy10 Based on 12 Wall Street analysts who have issued ratings for Krystal Biotech in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 2 have given a hold rating, and 10 have given a buy rating for KRYS. Consensus Price Target $324.118.24% Upside According to the 12 analysts' twelve-month price targets for Krystal Biotech, the average price target is $324.11. The highest price target for KRYS is $378.00, while the lowest price target for KRYS is $284.00. The average price target represents a forecasted upside of 8.24% from the current price of $299.45. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for KRYS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Krystal Biotech and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KRYS Analyst Ratings Over TimeTypeCurrent Forecast5/25/25 to 5/25/261 Month Ago4/25/25 to 4/25/263 Months Ago2/24/25 to 2/24/261 Year Ago5/25/24 to 5/25/25Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)1 Strong Buy rating(s)Buy10 Buy rating(s)9 Buy rating(s)9 Buy rating(s)7 Buy rating(s)Hold2 Hold rating(s)2 Hold rating(s)1 Hold rating(s)1 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$324.11$326.25$318.75$211.13Forecasted Upside8.24% Upside19.72% Upside19.43% Upside68.83% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyBuy KRYS Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History KRYS Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Krystal Biotech Stock vs. The CompetitionTypeKrystal BiotechMedical CompaniesBroader MarketConsensus Rating Score 2.83 2.30 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside8.24% Upside1,718.95% Upside15.09% UpsideNews Sentiment RatingPositive NewsSee Recent KRYS NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/18/2026 HC Wainwright4 of 5 starsJoseph Pantginis3 of 5 starsReiterated RatingBuy$310.00+1.21%5/5/2026 Evercore3 of 5 stars Reiterated RatingOutperform$300.00-0.49%5/5/2026 Citigroup4 of 5 starsYigal Nochomovitz4 of 5 starsBoost TargetBuy$371.00 ➝ $378.00+32.66%4/9/2026 Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeHold (C+) ➝ Buy (B-)3/27/2026 Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingKalpit PatelSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoveragePeer Perform2/25/2026 GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDebjit ChattopadhyaySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$224.00 ➝ $284.00+5.02%2/18/2026 Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingGeulah LivshitsSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$220.00 ➝ $323.00+12.22%2/17/2026 Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRoger SongSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$310.00 ➝ $371.00+25.66%2/5/2026 Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeStrong-Buy ➝ Hold1/30/2026 The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAndrea TanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$206.00 ➝ $327.00+17.06% Get the Latest News and Ratings for KRYS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. 1/22/2026 Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAlec StranahanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$288.00 ➝ $318.00+9.58%1/9/2026 TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingBuy2/20/2025 Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJosh SchimmerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOverweight$215.00+14.61%9/11/2024 Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetBuy$204.00 ➝ $220.00+18.92%8/30/2024 William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSami CorwinSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-BuyAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:53 PM ET. KRYS Forecast - Frequently Asked Questions What is Krystal Biotech's forecast for 2026? According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Krystal Biotech is $324.11, with a high forecast of $378.00 and a low forecast of $284.00. Should I buy or sell Krystal Biotech stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KRYS shares. Does Krystal Biotech's stock price have much upside? According to analysts, Krystal Biotech's stock has a predicted upside of 8.24% based on their 12-month stock forecasts. Has Krystal Biotech been upgraded or downgraded by Wall Street analysts recently? Over the previous 90 days, Krystal Biotech's stock had 1 upgrade and 1 downgrade by analysts. What analysts cover Krystal Biotech? Krystal Biotech has been rated by research analysts at Citigroup, Evercore, Guggenheim, HC Wainwright, Weiss Ratings, and Wolfe Research in the past 90 days. Do Wall Street analysts like Krystal Biotech more than its competitors? Analysts like Krystal Biotech more than other "medical" companies. The consensus rating for Krystal Biotech is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how KRYS compares to other companies. Stock Forecasts and Research Tools Related Companies ONC Stock Forecast RVMD Stock Forecast INSM Stock Forecast BNTX Stock Forecast ROIV Stock Forecast MRNA Stock Forecast VTRS Stock Forecast GMAB Stock Forecast ASND Stock Forecast RGC Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Krystal Biotech RecommendationsHC WainwrightWall Street ZenCitigroupEvercoreWeiss RatingsWolfe ResearchGuggenheimChardan CapitalJefferies Financial GroupZacks ResearchThe Goldman Sachs GroupBank of AmericaTD Cowen This page (NASDAQ:KRYS) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
